Abstract
Brain injury constitutes a disabling health condition of several etiologies. One of the major causes of brain injury is hypoxia-ischemia. Until recently, pharmacological treatments were solely focused on neurons. In the last decades, glial cells started to be considered as alternative targets for neuroprotection. Novel treatments for hypoxia-ischemia intend to modulate reactive forms of glial cells, and/or potentiate their recovery response. In this review, we summarize these neuroprotective strategies in hypoxia-ischemia and discuss their mechanisms of action.
Keywords: brain injury, hypoxia-ischemia, pharmacological treatments, glial cells, neuroprotection
Current Pharmaceutical Design
Title:Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells
Volume: 23 Issue: 26
Author(s): Maria Ines Herrera*, Sofia Mucci*, George E. Barreto, Rodolfo Kolliker-Frers and Francisco Capani*
Affiliation:
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
Keywords: brain injury, hypoxia-ischemia, pharmacological treatments, glial cells, neuroprotection
Abstract: Brain injury constitutes a disabling health condition of several etiologies. One of the major causes of brain injury is hypoxia-ischemia. Until recently, pharmacological treatments were solely focused on neurons. In the last decades, glial cells started to be considered as alternative targets for neuroprotection. Novel treatments for hypoxia-ischemia intend to modulate reactive forms of glial cells, and/or potentiate their recovery response. In this review, we summarize these neuroprotective strategies in hypoxia-ischemia and discuss their mechanisms of action.
Export Options
About this article
Cite this article as:
Herrera Ines Maria *, Mucci Sofia*, Barreto E. George, Kolliker-Frers Rodolfo and Capani Francisco *, Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells, Current Pharmaceutical Design 2017; 23 (26) . https://dx.doi.org/10.2174/1381612823666170727145422
DOI https://dx.doi.org/10.2174/1381612823666170727145422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research Functional Renal MRI
Current Medical Imaging Edaravone May Prevent Ferroptosis in ALS
Current Drug Targets Renovascular Hypertension: Lesion Detection, Patient Selection, Treatment Options and Results
Current Hypertension Reviews Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Neurogenesis: Role for microRNAs and Mesenchymal Stem Cells in Pathological States
Current Medicinal Chemistry Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Acute Symptomatic Seizures in Geriatric Patients with Multiple Risk Factors - A Diagnostic Challenge
Current Aging Science The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Photodynamic Therapy For Non-Melanoma Skin Cancers
Current Cancer Therapy Reviews Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Preparation and Chemical Characterization of Eco-friendly ORMOSIL Nanoparticles of Potential Application in DNA Gene Therapy
Current Nanoscience Antiviral Activity of Jodantipyrin – An Anti-Inflammatory Oral Therapeutic with Interferon-Inducing Properties
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Wnt Signaling in Angiogenesis
Current Drug Targets The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets Induction of Serine Racemase Expression and D-Serine Release from Microglia by Secreted Amyloid Precursor Protein (sAPP)
Current Alzheimer Research Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions
Current Medicinal Chemistry